• Organon will present real-world findings on switching VA patients from Humira to Hadlima at the ACR annual meeting on November 9, 2026.
• The study covered 16,322 veterans who switched treatments, finding few returned to Humira while treatment adherence remained similar.
• Estimated VA savings totaled $132 million, with average per-patient pharmacy costs falling $8,100 in the first year following the switch.
• Hadlima exclusively replaced Humira on the VA’s national formulary in 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261107078326) on November 07, 2026, and is solely responsible for the information contained therein.